

PENT COOPERATION TREAS.

From the INTERNATIONAL BUREAU

PCT**NOTIFICATION OF ELECTION**

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents
 United States Patent and Trademark
 Office
 Box PCT
 Washington, D.C.20231
 ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 07 December 1999 (07.12.99)
International application No. PCT/GB99/01185
International filing date (day/month/year) 16 April 1999 (16.04.99)
Applicant CANHAM, Leigh, Trevor et al

Applicant's or agent's file reference
IPD/P2638/WOD

Priority date (day/month/year)
17 April 1998 (17.04.98)

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

05 November 1999 (05.11.99)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Olivia RANAIVOJAONA Telephone No.: (41-22) 338.83.38
---	---

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/00, 47/34, 47/02	A1	(11) International Publication Number: WO 99/53898 (43) International Publication Date: 28 October 1999 (28.10.99)
(21) International Application Number: PCT/GB99/01185	(74) Agent: BOWDERY, A., O.; D/IPD DERA Formalities, A4 Building, Room G016, Ively Road, Farnborough, Hants GU14 0LX (GB).	
(22) International Filing Date: 16 April 1999 (16.04.99)		
(30) Priority Data: 9808052.6 17 April 1998 (17.04.98) GB	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (<i>for all designated States except US</i>): THE SECRETARY OF STATE FOR DEFENCE [GB/GB]; Defence Evaluation and Research Agency, Ively Road, Farnborough, Hampshire GU14 0XL (GB).		
(72) Inventors; and		
(75) Inventors/Applicants (<i>for US only</i>): CANHAM, Leigh, Trevor [GB/GB]; DERA Malvern, St. Andrews Road, Malvern, Worcestershire WR14 3PS (GB). BARRETT, Christopher, Paul [GB/GB]; DERA Malvern, St. Andrews Road, Malvern, Worcestershire WR14 3PS (GB). BOWDITCH, Andrew, Paul [GB/GB]; DERA Porton Down, Salisbury, Wiltshire SP4 0JQ (GB). COX, Timothy, Ingram [GB/GB]; DERA Malvern, St. Andrews Road, Malvern, Worcestershire WR14 3PS (GB). WRIGHT, Peter, John [GB/GB]; DERA Malvern, St. Andrews Road, Malvern, Worcestershire WR14 3PS (GB).	Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: IMPLANTS FOR ADMINISTERING SUBSTANCES AND METHODS OF PRODUCING IMPLANTS



(57) Abstract

A porous silicon implant (42; 60) impregnated with a beneficial substance, such as a micromineral required for healthy physiology, is implanted subcutaneously and is entirely corroded away over the following months/year to release the micromineral in a controlled manner. In a second embodiment the implant (62) may have a large number of holes (72) which contain beneficial substance and which are closed by bio-erodable doors (76, 78) of different thickness so as to stagger the release of the beneficial substance over time as the doors are breached.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
RJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IMPLANTS FOR ADMINISTERING SUBSTANCES AND METHODS OF PRODUCING IMPLANTS

This invention relates to implants for administering substances. One 5 embodiment of the invention is especially, but not exclusively, applicable to implants for administering micronutrient, or trace elements or minerals.

Drugs are most often currently administered orally by the ingestion 10 of tablets, capsules or aerosols, or via subcutaneous, intramuscular or intravenous injections or implants. Oral solid dosage forms account for 40-50% of the market, parenteral products - 33% and the other more "novel" dosage forms (NDF's), only a few %. There is nonetheless enormous perceived potential for NDF's that can enhance a drug's therapeutic ratio and avoid patient non-compliance. Non-compliance remains a major issue 15 despite 95% of patients being aware of its consequences. Common examples are incomplete courses of antibiotic therapy, using antidepressive drugs for too short a period, and forgetting to take contraceptive pills.

There are known implants that are implanted subcutaneously and 20 which deliver a drug over a period of time in a controlled manner. These are typically based on polymer material systems. There are two basic types of implant for controlled drug delivery: "reservoir" and "monolithic" structures. "Reservoir" devices have layers which are corroded or absorbed by the body to release a depot of drug beneath these control layers. By 25 having successive alternate control layers and drug layers the drug can be released over a period of time. "Monolithic" devices have the drug distributed throughout, so that release kinetics are controlled by slow corrosion and diffusion processes.

Problems include the so-called "burst effect" wherein an unwanted high fraction of the drug is released from the polymer capsule's internal surface quite soon upon in-vivo exposure. Another problem is the continuing need for high-purity, cost effective hosts that are capable of 5 sustained drug delivery over months or years (for some applications).

Other known implants include inert ceramic implants which have the drug held in their pores, the drug having to leave the ceramic implant via a tortuous path of micropores, which delays its release and allows it to be 10 controlled.

This invention concerns slow-release tissue-compatible implants, particularly suited to delivering low payloads of a therapeutic substance to a specific site and/or over a long period of time ("long" may be months or 15 years). Although delivered to the site of the implant the beneficial substance may be taken up by the body globally, and may have an effect at another site. In the past the major limiting factor for most drug delivery systems that use implanted materials (polymers or ceramics) has been the "payload" achievable. With the advent of new genetically engineered, more 20 potent drugs (peptides, proteins, DNA fragments), miniaturised delivery systems are becoming more and more attractive, provided designs ensure patient safety. An example of such a safety issue for in-vivo administration would be the failure of an electronic "gate" linked to a large on-chip liquid reservoir. Such concerns can be addressed by the use of drug delivery 25 arrays or drug incorporation within a resorbable host material.

The invention also concerns impregnation of porous semiconducting materials including porous silicon. It is advantageous to have implants comprising porous semiconducting materials that have been impregnated 30 with one or more beneficial substances. It is also advantageous to have the

concentration of such a substance or substances as high as possible and as deep as possible from the surface of the porous semiconducting material. A problem with prior art methods of impregnation, for example those disclosed in the paper entitled: "Impregnation of porous silicon" by R Herino (EMIS datareview on porous silicon (1997)) p66 or the paper entitled "Quenching of porous silicon photoluminescence by deposition of metal adsorbates" by D Andsager, J Hilliard, J M Hetrick, L H Abu Hassan, M Pilsch and M H Nayfeh, reported in J. Appl. Phys. (1993), 74, 4783, is that the depth of impregnation is very low, typically a few atomic percent at 300 nm or less.

According to a first aspect the invention comprises a silicon implant provided with a substance to be administered to the implanted subject.

Preferably the implant comprises porous silicon. The porous silicon may have a porosity of at least 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or higher (the porosity is the fractional void content by volume). The porous silicon may have a porosity that is in a range between any two of the figures mentioned above.

The implant may have a coating, region, or layer of silicon, or it may be silicon substantially throughout its cross-section. The implant may have a layer of material over the silicon, for example a coating of hydroxyapatite. The over-layer of material may have a physiological effect upon implanting of the implant.

The silicon may be polycrystalline silicon.

Said substance may be distributed in the solid phase silicon material substantially uniformly. In the case of porous silicon said substance may be

distributed in the pore network and/or in the silicon skeleton. It is envisaged that distributing the substance in the material of the skeleton may give greater control over the release rate of the substance since this will be related directly to the erosion rate of the silicon material. With a substance held in pores the release rate is also dependent upon how quickly the material can escape the pores (before the skeleton has eroded). This may or may not be desirable or acceptable. In the case of polycrystalline silicon the substance could be distributed in the grains and/or grain boundaries.

10 It has been appreciated that silicon, and in particular porous silicon, has very good properties which enable it to serve as a drug or micronutrient delivery vehicle. Experimental evidence in support of the suitability of porous silicon as a substance delivery vehicle in an implant has been obtained. Studies by the inventors have shown that porous silicon is "resorbable" or "bio-erodible", and is resorbed or eroded by the mammalian body at a slow enough rate to make long-term porous silicon implants a practical way to deliver drugs/substances.

20 Highly porous silicon has long been known to be unstable structurally and chemically, and researchers in the opto-electronics field have gone to great lengths to make it more stable for opto-electronic applications. It is ironic that the lack of stability/inert properties of porous silicon now, with hindsight, is a factor in the controlled delivery of substances by implants.

25 Tests show that high porosity (e.g. 80%) silicon is resorbed faster than medium porosity (e.g. 50%) silicon, which is in turn resorbed faster than bulk silicon (which shows little, if any, signs of being resorbed). Thus, by adjusting the pore size and total volume of pore to skeleton in

porous silicon it is possible to tune the silicon material to be resorbed faster or slower.

5 Microporous silicon (pore size less than 2 nm), mesoporous silicon (pore size 2-50 nm) and macroporous silicon (pore size >50 nm) are all suitable carrier materials for erosion.

10 Silicon is cheap, and is available in very pure forms (e.g. the electronics industry already has a requirement for clean, pure, silicon wafers). Moreover, it is already known how to dope silicon crystals with a very wide range of elements, albeit in a different field and albeit at very low concentrations (lower concentrations than required for micronutrients).

15 It is envisaged that having a beneficial substance provided in porous silicon implant as a delivery mechanism will be especially appropriate for delivering substances which do not need to be delivered at high doses. It is envisaged that a porous silicon implant may be about 0.5 x 0.5 x 4 mm in size (or in the ranges >0 to 2 mm x >0 to 20 mm x >0 to 20 mm). Each implant may have a weight of less than a milligramme, or a few milligrammes, or a few tens or hundreds of milligrammes. and each tablet may conveniently be doped with a "dry payload" of tens to hundreds of microgrammes of substance, or even to a few milligrammes (or more if it is possible to carry it). This may be insufficient for delivery of macronutrients, or macro dose drugs, but it is sufficient to deliver substances which are needed in the micro to milligramme range.

20 One area where porous silicon is suitable as a carrier for a therapeutic or beneficial substance is in the provision of micronutrients or microminerals to subjects.

Some trace minerals needed by the body are present at extremely low concentration in the body (e.g. selenium, chromium, manganese and molybdenum). The recommended daily allowance (RDA) of microminerals can be <0.1 mg/day and yet deficiency effects are well documented (e.g. 5 selenium iodine). This is often because only a small and highly variable fraction of orally-ingested microminerals are absorbed and hence become bio-available. Having these microminerals delivered by an implanted silicon tablet that is fully adsorbed is an attractive solution to deficiency problems. Moreover, by having the substances in an implant it is possible 10 to deliver a substance to a specific site (e.g. iodine to or near the thyroid gland).

Silicon itself is an essential trace element, and a porous silicon implant could, of course, be used to deliver silicon in which case it may not 15 carry any other beneficial substance.

The implant may have more than one beneficial substance. A multi-essential trace element implant having 2, 3, 4, 5 or more trace elements may be provided.

20 Other elements have widespread use clinically for therapeutic purposes, e.g. lithium for depression, gold and silver for antibacterial properties, and platinum for neoplastic diseases. These may be administered not so much to achieve a desirable "normal" mineral content 25 in the physiology of a subject, but to increase levels of microminerals to therapeutic levels, possibly at a specific locality. The dose levels of such therapeutic elements in the blood stream are normally in the µg/l range, which is within the capabilities of porous silicon implants. The implant may comprise a porous silicon sample in which such an element (whether it be a 30 trace element or an element in a beneficial substance or some other element

of the periodic table) has been impregnated at a concentration between 1 and 90 atomic percent at a depth, from the surface of the sample, between 0.35 μm and 1000 μm . More preferably the element may be present at a concentration between 1 and 90 atomic percent at a depth, from the sample 5 surface, between 1 μm and 1000 μm . Yet more preferably the element may be present at a concentration between 1 and 90 atomic percent at a depth, measured from the sample surface, between 10 μm and 1000 μm . Even more preferably the element may be present at a concentration between 30 μm and 1000 μm . It is often advantageous for such elements to be released into the 10 body of the mammal at a slow rate. To facilitate this slow release it is advantageous to provide high concentrations of such elements at relatively large depths from the surface of the porous silicon.

A therapeutic or essential trace element (or other element) may be delivered 15 in non-elemental form. For example, a salt of a metal may be the beneficial substance, metal ions being available to the body of the patient. So long as the substance is delivered in a physiologically usable form, how it is carried in the erodable material (compounded or elemental) may not matter.

It will be appreciated that implanting an implant which can deliver a controlled amount of a drug/micronutrient/micromineral for a month, or even two or three months, or a year, or possibly even years, has great advantages over relying on a patient to eat correctly or take oral tablets correctly, especially when the disorder being treated exacerbates any difficulties in the patient having a discipline to take the remedy. The fact 25 that a silicon implant can be made to break down slowly makes it possible to leave an implant alone for a long time. When a sustained level of drug dose delivery is required a silicon implant can be engineered to deliver a prolonged sustained substantially constant (or constant enough for the 30 intended purpose) level of drug or mineral. Using implants to deliver trace

elements is attractive for those people who have gastrointestinal tract disorders and who cannot absorb some elements orally. Even if a patient were to be treatable orally there can be a great variation in the level of absorption achieved in people's guts and the same level of oral dietary supplement may result in different levels of absorbed mineral. Subcutaneous absorption has significantly less variation between people and is therefore more easily controlled.

A feature of virtually all drugs, especially large organic molecules, however is that they cannot survive high temperatures. If a silicon implant is made using high temperature doping techniques it may not be possible to get the structural silicon material of the implant to take up some molecules in a functional state. However, this is not a problem for therapeutic elements (e.g. Li, Se, etc.).

15

Of course, it is possible to use techniques other than thermal drive in to get drugs into the depths of an implant and/or into the solid phase of the porous skeleton. We could use vacuum evaporation, or build the implant up in layers, with the substance adhering predominantly to the surface of each layer, or indeed any suitable technique for distributing the substance throughout the body of the erodable implant.

The geometric design of known monolithic drug release implants can be used to control the drug release rate, and similar techniques of geometric design can be used to control substance release from silicon implants. This may be in addition to controlling the porosity, and pore size of porous silicon to control the rate of dissolution of the implant. The implant may have different porosity at different depths.

Of course, the silicon implant need not necessarily have its erodable carrier material of pure silicon, or substantially pure silicon. Now that it has been established that silicon works it is predictable that silicon carbide and silicon nitride may also have similar properties. Indeed, as a 5 generalisation, a silicon-based compound which has the corrosion properties desired (corroding at a generally constant rate over months or years) and which is non-toxic at the levels released, and which otherwise has no unacceptable harmful effects, would be suitable in place of pure (or substantially pure) silicon as the carrier material, but silicon is still 10 currently preferred.

According to a second aspect the invention comprises a porous or polycrystalline implant provided with a substance to be administered to the implanted subject, the implant being made substantially of an element.

15

Preferably the implant is made of porous or polycrystalline semiconductor.

Although tests by the inventors *in vivo* show that porous silicon is 20 corroded if subcutaneously implanted, the inventors also have *in vitro* tests using simulated body fluid (SBF) which shows that porous and polycrystalline silicon behave in a similar way in SBF.

The realisation that silicon, and especially porous silicon and/or 25 polycrystalline silicon, are suitable materials to be bio-eroded by the body in a controlled manner, and the realisation that this can be used to release drugs/substances into the body (or to a localised area), can be further expanded. The implant may have a plurality of drug payload areas defined 30 in a body of silicon, the body of silicon having a plurality of barrier regions, or doors, adapted to be resorbed in use by the body, the geometry

10

and size of the barrier regions being such that in use at least a first barrier region is eroded or resorbed such that the drug payload in the drug payload area adjacent said first barrier region is released to the body before a second barrier region, adjacent a second drug payload area, is resorbed sufficiently 5 to enable the second drug payload to be released, thereby providing a time-differential breakdown of at least the first and second barrier areas and hence a sequential release of said first and second drug payloads.

The first and second drug payloads may comprise the same drug, or
10 different drugs.

There may be three or more barrier regions each adapted to be corroded at different times, and adapted to release drug payloads from respective drug payload areas at different times.

15

The barrier regions may comprise porous silicon, such as mesoporous silicon or microporous silicon. The barrier regions may comprise polycrystalline silicon. The rate of erosion of the silicon can be controlled by controlling the porosity (higher porosity materials are corroded faster) and the pore size (smaller pores for same porosity are corroded faster), and the barrier thickness.
20

Instead of having one implant with a plurality of drug payloads it may be desirable to provide a plurality of separate implants with drug 25 payloads and barrier regions adapted to release the drug payloads at different times.

The implant may comprise a tablet. The tablet may comprise an array of drug payload reservoirs each containing a respective drug payload.
30 The tablet may have a longitudinal direction and the respective barrier

regions associated with respective drug payloads may be spaced apart in the longitudinal direction. The implant may be adapted to be corroded in a direction transverse to the longitudinal direction, and preferably at right angles to it, in order to release the respective drug payloads. The implant
5 may have a longitudinally extending surface portion and the drug payload areas may be separated from the surface portion by barrier regions requiring different times of attack by body fluids to be corroded. The different corrosion times of the different barrier regions could be afforded by different thicknesses of barrier region. Alternatively, or additionally, the
10 silicon material of the implant may have different corrosion properties at different barrier regions (e.g. they could be made of porous silicon of different porosity).

According to a third aspect of the invention a method of impregnating a
15 porous semiconducting material with a impregnate substance is provided, the method comprising the step of bringing the impregnate substance into contact with the porous semiconducting material; characterised in that the method further comprises the steps:

- 20 (a) causing the impregnate substance to be in a molten phase; and
(b) allowing the molten impregnate substance to pass into the porous semiconducting material.

It is advantageous for some applications, for example medical applications,
25 to have a method of impregnating substances at a depth of at least several hundred nanometres below the surface of a porous semiconducting sample. It has been found that high depths of impregnation can be achieved by ensuring that the substance to be impregnated is in a molten phase.

Preferably the method of impregnating a porous semiconducting material further comprises the step of thermally decomposing the impregnate substance that has passed into the porous semiconducting material.

- 5 Advantageously the method of impregnating a porous semiconducting material comprises the step of reacting the impregnate substance that has passed into the semiconductor material with an oxidant, such as oxygen.

- 10 The impregnate substance may be fixed to the porous semiconductor by thermally decomposing it once the substance has entered the interior of the semiconductor. Alternatively the impregnate substance can be fixed to the porous semiconductor by reacting with an oxidant such as oxygen.

- 15 Throughout the specification the term "sample surface" is to be taken to mean the surface that separates the sample of porous semiconductor (including porous silicon) from its surroundings. The term does not mean the surfaces that define the pores, unless such surfaces form part of the surface that separates the porous semiconductor from its surroundings.

- 20 According to a fourth aspect the invention provides a sample of porous silicon that has been impregnated with an impregnate substance, the sample having a sample surface and the impregnate substance comprising an impregnate element, characterised in that the impregnate element is present at a concentration between 1 and 90 atomic percent at a depth, from the
25 sample surface, between 0.35µm and 1000µm.

Embodiments of the invention will now be described by way of example only, with reference to the accompanying drawings, in which:-

Figures 1A to 1D show scanning electronic micrographs at x3000 magnification of a titanium implant explanted from a guinea pig at 0, 1, 4, and 12 weeks after implant, respectively;

5 **Figures 2A to 2D** show scanning electronic micrographs at x3000 magnification of a porous silicon implant explanted from a guinea pig at 0, 1, 4 and 12 weeks after implant respectively;

10 **Figures 3A to 3D** show scanning electron micrographs at x3000 magnification of a porous silicon implant partially coated with hydroxyapatite (HA) and explanted from a guinea pig at 0, 1, 4, and 12 weeks after implant respectively;

15 **Figure 4A** shows schematically a silicon wafer micromachined to form thousands of implants;

Figures 4B and 4C show two implant structures;

20 **Figure 5** shows a table of elements which may be administered using the present invention, those elements being indicated by the key as being essential trace elements, and/or having deficiency problems are those which are preferably incorporated in an implant:

25 **Figure 6** shows another embodiment of the invention in which there are a plurality of drug payloads provided on a resorbable tablet;

Figures 7 to 9 show alternative multi-drug tablet implants;

30 **Figure 10** shows the mean (+/- sem) daily temperature for each of the four groups of guinea pigs;

Figure 11 shows mean (+/- sem) daily weight for each of the four groups of guinea pigs;

5 Figure 12 shows a comparison of guinea pig mean (+ sem) temperature for the 7 day control period and for the subsequent 1, 4, 12, and 26 week periods; and

10 Figure 13 shows a comparison of guinea pig mean (+ sem) weight gain for the 7 day control period and for the subsequent 1, 4, 12, and 26 week periods.

15 Figures 1A to 1D show that over a 12-week period of tests a titanium implant subcutaneously implanted in a guinea pig exhibits little change to its surface - it is bioinert.

20 Figures 2A to 2D show that when a porous silicon subcutaneous implant (30% porosity) is examined at 0, 1, 4 and 12 weeks there are substantial changes to the porous surface of the implant. There is considerable corrosion of the porous silicon, even to the extent that the layer of porous silicon above the bulk silicon body (upon which the porous silicon is formed) was totally eroded at places.

The discs used in the in-vivo trials were made as follows:

25

(a) **Titanium Discs**

30 Titanium foil of 99.6+% purity was purchased from Goodfellow Metals Limited in the form of punched-out discs of 0.5 mm thickness and diameter 11.5 mm. These were subsequently abraded (on both faces)

with 12 μm diamond powder to remove any burrs introduced by the punch-out process and to develop equal degrees of surface roughness on both faces. Batches of 10 discs were then chemically etched at a time after cleaning in an ultrasonically agitated acetone bath for 20 minutes. The 5 discs were isotropically etched (to remove surface damage) for 2 minutes in a stirred solution of 35 ml H_2O , 10 ml HNO_3 , and 5 ml 40% HF. The etch process was quenched with DI water and discs were thoroughly rinsed in DI water prior to drying on filter paper.

10 (b) Bulk Silicon Discs

Batches of 12 mm wide discs were sawn out of ~5" (100 mm) diameter CZ wafers (N^+ , phosphorous-doped 0.0104.0.0156 Ωcm resistivity, 0.5 mm thick, (100) orientation) using a custom-built drill bit. Discs were 15 cleaned in "meths", then ethyl acetate and then in an ultrasonically agitated acetone bath. Smoothing of the disc edges, removal of saw damage and equality of surface roughness on both faces was achieved using a "polish etch": 25 ml HNO_3 + 5 ml HF (40%) + 5 ml acetic acid. Batches of 10 discs at a time were given a 5-minute etch with continuous stirring followed 20 by a DI H_2O quench and rinse with drying on filter paper.

(c) Porous Silicon Discs

The chemically polished bulk Si discs were anodised sequentially, 25 one at a time, in a custom-built electrolytic cell that enabled both faces and edges to be porosified. Discs were held at one edge by a platinum "croc-clip" and lowered and raised in a controlled manner by a stepping motor into electrolyte in a cylindrical Pt crucible that formed the cathode. Each disc was anodised potentiostatically (i.e. at a constant voltage 30 of 1.0 V) in 40% aqueous HF for a period of 10 minutes. With this type of

arrangement most current flow occurs via the meniscus, so the procedure adopted was to slowly raise the meniscus up to the centre of the disc, remove the half-anodised disc, dry it and then invert it, to anodise its other half in the same manner. Fully anodised discs were by this process 5 completely covered in an ~30 μm thick coating of porous silicon. They were rinsed in DI H₂O and dried on filter paper.

(d) Sterilisation

10 All discs were stored in air prior to sterilisation by "autoclaving" at 134°C for 10 minutes in pressurised steam.

Figures 3A to 3D show similar corrosion/resorbtion of coated porous silicon, 30% porosity, (coated with hydroxyapatite). The rate of corrosion 15 appears to be slower for the coated porous silicon. Coating the silicon with other materials may delay, or speed up corrosion at early stages, depending upon the coating material used. This can be used to give a high initial dose of substance and then a lower dose (possibly for a prolonged time), or a low initial dose (or no dose) initially, followed by a higher dose later.

20 Figures 2 and 3 show that the corrosion of porous silicon in mammals does take place, and in a progressive manner.

Tests were also done to ensure that the silicon implants did not cause 25 any serious problems to the guinea pigs, and again these tests show that using silicon, and especially porous silicon, as a biologically acceptable material is viable in a subcutaneous site. The pathological test results are given in the sections, presented below, entitled "In vivo trial of Porous Silicon Implant" and "Score grades" which forms part of this patent 30 application.

The 12-week tests described above have been followed by a 26-week study which has shown entirely consistent results: there is a steady corrosion of porous silicon, and the corrosion of the implants did not cause
5 any significant harmful effects on the test subjects. There was no gross inflammatory response, no significant fibrotic scarring, and excreting the corroded silicon was not a problem.

Since the corrosion of polymer is known and tested as a delivery
10 mechanism for drugs, the present invention is, with the support of the tests discussed, fully realisable. Nevertheless the concept of using semiconductor tablets for prolonged in-vivo drug delivery is completely novel.

15 Figure 4 shows a silicon disc 40 machined to produce many thousands of implant tablets 42. It is envisaged that hundreds or thousands of tablets could be made from an 8 inch (200 mm) diameter wafer.

20 The wafer is treated so as to cause it to become porous throughout its depth, and then broken into discrete tablets. The tablets are then smoothed to facilitate subcutaneous insertion and acceptability. An elongate tablet, such as that shown, may be suitable for injection through a needle. The rounded ends 44 of the elongate tablet may help this. The tablets may take the form of that shown in Figure 4B.

25

In an alternative arrangement shown in Figure 4C a disc 46 of about 20-25 mm diameter is shown. This is surgically subcutaneously implanted.

30 It will be appreciated that the implants 42 and 46 are completely eroded in the body and do not need surgically removing.

Figure 5 shows elements considered suitable for incorporation into silicon implants which rely upon the corrosion/resorbtion of the silicon material to deliver an active substance (the element). It is envisaged that 5 implants will be provided having one or more of the elements indicated as being essential trace elements, and most preferably those indicated as being essential trace elements with deficiency problems.

It is also, of course, envisaged to administer therapeutic elements or 10 substances for particular disorders.

Furthermore, in the case of a problem associated with an excess of an element, or excess of a substance, the implant could be used to administer a blocker to prevent the excess substance operating properly, or something to 15 bind to or react with the excess substance, reducing the effective excess. For example, it has been proposed that silicon in the form of silicic acid can beneficially assist in aluminium excretion.

There is no theoretical reason why an element such as iron cannot be 20 administered using the present invention, but it may as a practical matter be difficult to get a sufficiently high dose of Fe into a silicon tablet to make it sensible to implant an implant.

Elements which are preferred for incorporation into a silicon 25 micromineral tablet include: Vn, Cr, Mn, Se, Mo (dietary requirements), Li, Ag, Au, Pt (therapeutic effect).

As well as silicon other suitable biocorrodable semiconductors to use 30 as carriers for beneficial substances include germanium, silicon carbide and silicon nitride. The semiconductor material could be doped or undoped.

Silicon carbide may have anti-thrombogenic properties, and silicon nitride may have orthopaedic applications.

There is no reason why molecules, as well as elements, cannot be delivered, so long as the technique for getting the drug/desirable substance into the implant does not destroy the efficiency of the substance, and so long as they are released in a form which is active when the silicon is broken down.

10 In the case of minerals/trace elements one way of producing micromineral tablets is:

- (1). create porous silicon: for example by anodising a whole silicon wafer to introduce a low concentration of mesopores (e.g. 30% porosity) - this is done using HF acid and an electric potential in a known manner (see for example US Patent 5 348 618 which discusses creating porous silicon using HF acid to achieve partial electrochemical dissolution - the contents of US 5 348 618 are hereby incorporated by reference);
- 20 (2). use wafer dicing and wet-etching techniques that are standard in the silicon semiconductor industry (or any other techniques) to define smooth tablets (sharp edges are undesirable);

25 The order of (1) and (2) may be reversed.

- (3). impregnate the tablets: for example by immersing them in an aqueous solution of the mineral, or minerals, to be impregnated (the tablets could contain more than one mineral) and then driving in the

20

minerals using a thermal drive-in technique. for example put the saturated tablets in an oven at 800°C for thirty minutes:

(4). clean the tablets (if necessary).

5

Another way of getting a substance into the implant is to put a salt of a mineral on the surface, heat in an inert atmosphere (e.g. argon) until the material melts and wets the porous structure. The insert/wafer can then be cooled down, and any excess substance washed off in water. A thermal drive in operation can then be performed.

10

It is preferred to drive the mineral into the solid phase of the porous structure, rather than leave it solely in the pores. This gives greater control of the dissolution rate of the mineral and eliminates the "burst-effect" problem common with polymer-based systems.

15

A combination of a knowledge of the dissolution rate of the tablets, and how that behaves with time, and the doping level of the tablets, and how uniform that it, gives the ability to control the dosage of substance administered over time.

20

Figure 6 shows a schematic cross-section of a multi-reservoir silicon tablet 60 (not to scale). The tablet 60 comprises a first portion 62 joined, for example by medical adhesive (or by wafer bonding), to a second portion 64 at interface 65. In this example, the first and second portions are mirror images of each other, and are identical (they are symmetric). Each half 62 or 64 of the tablet has side peripheral, or rim, portions 66 and a top (or bottom) wall portion 68. Each half of the tablet has micromachined in it a large number of reservoirs 70 which, in the assembled finished tablet, 25 contain drug material 72. The reservoirs are separated by island walls 74 of

30

silicon. The tablet 60 (including the rim portions 66, top/bottom portion 68, and island walls 74) is made of resorbable porous silicon which is corroded and absorbed by the body when implanted. The fact that the two portions 62 and 64 are substantially identical makes it cheaper to
5 manufacture them since there is only one shape to machine.

In the example shown in Figure 6, distance D4 is shortest and the wall thickness in the region D4 is breached first by corrosion of the porous silicon, releasing the contents of reservoir R1 first. Next reservoirs R2 and
10 R3 are released as the next thinnest wall portions 76 in those regions corrodes away and is breached. Then wall portions 78 corrode releasing the contents of reservoirs R4 and R5, and so on.

By having barrier walls of different thicknesses it is possible to
15 achieve controlled - and sustained - drug release as reservoirs are sequentially opened.

The distances D1, D2 and D3 are such that the "lid" thickness D4 is significantly thinner than the rim thickness D2. Thus, the micromachining
20 of the depths of the reservoirs controls the release time of the outer reservoir, rather than its proximity to the peripheral edge of the silicon wafer. Similarly, D3 is large enough between adjacent reservoirs that it is the "lid" thickness that is corroded first, and not the island walls 74 between adjacent reservoirs (after one reservoir has already been opened to
25 body fluids corrosion of the island walls occurs).

Of course, we may prefer to have the progressive opening of reservoirs achieved by corrosion of the dividing walls between adjacent reservoirs, instead of or in addition to the corrosion of peripheral surfaces
30 of the tablet.

It will be appreciated that the reservoirs of drug material could hold beneficial substance in any form, for example liquid drug, or powder drug, or solid drug. The drug could be a complex organic molecule, or it could be 5 a micronutrient or micromineral as previously discussed.

The reservoirs of drugs could contain a micromineral tablet, or other tablet/implant. A reservoir hole may contain a plurality of erodable drug/element delivery tablets/implants, which may contain the same or 10 different beneficial substances, and/or may be corroded at different/the same rates. Thus, the doors to reservoirs may be separately eroded to allow physiological access to tablets which in turn release a beneficial substance in a controlled manner over days, weeks or months. There may be several tablets in a reservoir, or tens of tablets, or hundreds of tablets.

15

The "reservoirs" need not necessarily be machined holes in a body of resorbable porous silicon material, they could be regions which have been differentially impregnated with a beneficial substance in comparison with the "walls" (or they could be regions which otherwise have a differential 20 level of beneficial material in comparison with the "wall" regions). Thus, the implant may be a solid body (possibly made from discrete sections, but with no actual holes). However, at present, it is envisaged that micromachining an array of holes will probably be best.

25

The wall regions can be considered to be time delay means adapted to delay the timing of release of the contents of the reservoirs.

30

It will be appreciated that silicon technology is indeed ideally suited to compartmentalising drug payloads - an attribute that is exploited in this invention. The basic idea is to micromachine an enormous number (e.g.

$10^2\text{-}10^4$) of independent reservoirs into resorbable blocks of Si. thereby generating a new way of controlling kinetics of drug release. The time of release from each reservoir is predetermined by the overlying thickness of a microporous "lid" that is gradually eroded in-vivo.

5

The example of Figure 6 may be created by anodising right through two Si wafers, then deep dry etching an array of photolithographically defined cavities in both, and finally bonding them together after reservoir filling. The kinetics of release are determined by the volume distribution and lid thickness distribution within the array. For this to be the case the diffusion time of a high molecular weight drug (which may be a typical drug) through the "lid" is made infinitely long compared with its erosion rate. This is achieved via lid topography (use of micropores < 2 nm width) or pore surface chemistry (e.g. hydrophobicity with hydrophilic drugs).
10 Alternatively the drug deposit is itself in solid form until the physiological fluids break through into the reservoir.
15

The arrangement of Figure 6 is one way of providing a multi-reservoir, time-differential release implant. Similar effects can be
20 achieved by the implant 71 of Figure 7 which shows a lid 73 made of very slowly corroded material and a base 75 made of faster corroding material. A flat interface between the lid 71 and the base 73 may make it easier to assemble the implant. The depths referenced 77 control the release time of the reservoirs.

25

One of the reservoirs in Figure 7 is shown containing a number of micromineral porous silicon tablets 79. The lid 73 could, of course, be made of a material that corrodes at the same rate as the base (e.g. of the same material).

30

Figure 8 shows an arrangement and a flat lower surface 86. The profile of the lid matches the "doors" of the base so as to achieve breakthrough of the lid and base at regions adjacent any particular reservoir generally at the same time.

5

Figure 9 shows an implant 90 having a base and a lid 92. The base 91 has reservoirs 93 of generally the same depth, and barrier regions 94 of generally the same depth. The lid 92 has a stepped/profiled upper surface topography arranged to ensure sequential, time-differentiated, 10 breakthrough into the reservoirs (the lid is corroded through first, not the base).

The multi-reservoir implanted discussed are all fully resorbable, and do not require surgical removal, but the invention is also applicable to 15 non-corrodable implants having corrodable doors. The non-corrodable part of the implant may be bulk silicon.

The above types of delivery system offer much better control and predictability of delivery rates than conventional "monolithic" polymer 20 systems. In the latter case drug release rates are often determined by diffusion through a tortuous pore network. at least for sustained release.

It will also be appreciated that the technical effect achieved by the embodiment of Figures 6 to 9 can be achieved using other corrodable 25 materials beyond silicon. Indeed: in one aspect the invention is not restricted to silicon material for the construction of a multi-reservoir progressive drug release implant. Any suitable material may be used.

According to another aspect the invention comprises an implant 30 having a plurality of reservoirs, a plurality of beneficial substance charges

provided on said reservoirs, and a plurality of barrier regions, or doors, provided adjacent said reservoirs, the doors having a plurality of different erosion times when implanted, the arrangement being such that in use the doors are broken down sequentially in order to stagger the release of the
5 contents of the reservoirs.

There may be up to ten reservoirs, of the order of tens of reservoirs, or even of the order of hundreds of reservoirs, or more.

10 The invention also comprises a method of timing the release of beneficial substances in an implant.

15 The fact that silicon does not resorb too quickly is beneficial. It is preferred to have an implant that will not need replacing for at least one month, and most preferably for at least two months, three months, four months, six months, nine months, or a year or more.

20 A problem with using the erosion of an implant to deliver drug embedded in the material of the implant is that the surface area of the implant changes with time (or can change with time) and hence the drug delivery changes with time. For example, a sphere gets smaller. This can in part be countered by the geometric design of the implant to allow the creation of an expanding internal surface to compensate for a contracting external surface.

25 An alternative, or complementary, approach that is now realisable with porous silicon, and with polycrystalline silicon, is to ensure that the drug/beneficial substance is present at different concentrations at different regions of an implant. This can be achieved by controlling the pore size
30 through the depth of a body of porous silicon, or by controlling the grain

size/number of grain boundaries. The number and/or size of grain boundaries may be controlled throughout the depth of a body of polycrystalline silicon. Thus, it is possible to have a porous silicon tablet which has a substantially uniform dose delivery rate with time as it is resorbed due to the concentration of drug/micromineral in it increasing towards its centre so as to balance the decrease in exposed surface area.

It will be noted that substantially 2-dimensional shapes, such as a disc, do not suffer so much from changes in surface area, and neither do the elongate "line" shapes (as shown in Figures 4B and 4C).

In addition to the porosity affecting the amount of substance that can be held in microporous silicon (greater porosity, greater substance-containing capability), the pore size can affect the rate of dissolution of the implant. Thus, the inner regions of a porous silicon implant can be arranged to corrode faster than the outer regions, again having a compensating effect for the loss of exposed surface area.

Whilst many countries do not, yet, permit the patenting of methods of treatment of the human or animal body by surgery or therapy, there are some (e.g. USA) who do. In order for there to be no doubt about the Paris Convention priority entitlement to such an invention in those countries that do permit it, the invention also comprises the treatment, therapeutic or prophylactic, of a disorder of the human or animal body by implanting a silicon implant and allowing the implant to corrode or be resorbed so as to realise a beneficial substance which helps to alleviate or ameliorate the disorder, or to prevent the disorder from occurring. The implant will typically be implanted subcutaneously.

Furthermore, the technique could be used to release diagnostic substances, possibly in a localised region of the body. Diagnostic substances are "beneficial substances".

5 It will be appreciated that the realisation that silicon structures, especially porous silicon and polycrystalline silicon structures are able to be broken down by the body over a long (months) period of time without evidence of significant harmful effects has led to the ability to create beneficial substance (e.g. micronutrients and drug) delivery implants which
10 take advantage of this. The evidence showing no detrimental effects of implantation enables us to have a reasonable and predictable expectation of success - it is more than speculation.

At present, it is perceived that restrictions on the physical size of the
15 drug payload for implants will restrict their practical use to delivering microminerals, or other substances, which are not required at high levels (e.g. genetically engineered proteins, peptides, and gene fragments, and other DNA material). However, the invention is not necessarily to be restricted to those areas if a practical macro-drug delivery implant is
20 created.

A "beneficial substance" is something beneficial overall: it could be a toxin toxic to undesirable cells/to interfere with an undesirable physiological process. For example, anti-cancer substances would be
25 considered "beneficial", even though their aim is to kill cancer cells.

It will be noted that the terms "eroded", "corroded", "resorbed" are all used herein. The mechanism of corrosion is not fully known, but that erosion, corrosion takes place is proved. Bioerosion, bioresorption,
30 biodegradation are other possible terms: at present whether the

silicon/carrier material is taken up into cells or stays extracellular is not considered important. It is not intended, necessarily, for the invention to be restricted to any precise biological distinction between the "corrosion" terms used.

5 Impregnation of Porous Semiconducting Materials

Experiments were carried out to demonstrate the impregnation, according to one aspect of the invention, of porous silicon samples with a number of metals (manganese, silver, and chromium) or compounds (for example 10 oxides) of these metals. A salt of the metal was placed on the surface of a sample of porous silicon. The temperature of the salt was raised until the salt melted. The molten salt then passed into the bulk of the porous silicon. The application of heat resulted in decomposition of the salt to yield the metal or the metal oxide.

15

The starting material was 3-5 ohm cm n-type (100) silicon. This was anodised in a 50/50 mixture by volume of ethanol and 40wt% hydrofluoric acid. The anodisation current was 100 mAcm⁻² and the anodisation time was 5 minutes. This gave a porous silicon film of thickness 30 microns and 20 gravimetrically determined porosity of 38%. Samples of the porous silicon (supported on the un-anodised bulk silicon) prepared by this method, were cleaved to make pieces approximately 2cm by 2cm in dimension.

25

The metal salts chosen were the manganese (II) nitrate, chromium (III) nitrate, and silver (I) nitrate. A general procedure, according to one aspect of the invention, was adopted. The nitrate was placed on the surface of the porous silicon sample. The sample of porous silicon was placed on a graphite block with the porous face upwards. On to the surface was placed an amount of the metal nitrate powder. The graphite block, with the porous 30 silicon wafer on it, was loaded into a CVD reactor. The reactor was

assembled and closed to the atmosphere. The CVD reactor was flushed with argon (to create an inert atmosphere) or hydrogen (to create a reducing atmosphere).

- 5 The sample temperature was then raised until the metal nitrate was observed to melt.

For some samples, following a period at this initial temperature, the temperature was raised further and the salt observed to decompose by the evolution of bubbles. After some time at elevated temperature the sample 10 was cooled to room temperature and removed from the CVD reactor. A number of the samples produced by this method were then washed in deionised water and dried. After washing, analysis of the metal content was performed by EDX on cleaved edges.

- 15 For each impregnation procedure, the sample of porous silicon was weighed prior to impregnation. After impregnation the samples were washed in deionised water and re-weighed. For each of the three nitrate salts tested, an increase in weight was observed. Since the three nitrate salts are all highly soluble in water, the increase in weight suggests that the nitrate salts were decomposed, presumably to either the 20 metal or an oxide of the metal, by the heat applied to the porous silicon sample.

The procedure for managanese (II) nitrate, which is consistent with the above mentioned general procedure, will now be described. Manganese nitrate powder, sufficient to give approximately 0.5 gram of powder per 1cm² of porous silicon surface, is placed on the surface of the porous silicon sample. Inert gas (argon) at a rate of 700 cm³/min was allowed to flow through the CVD reactor for ten minutes. At this point the temperature of the graphite block with the wafer upon it was raised to 50°C. The manganese nitrate was observed to melt and the temperature was maintained at this value (50 C) for one hour. The temperature was then raised to 30 150°C and maintained at this value for a further hour. At this stage gas evolution

from the molten salt was observed. The temperature was then allowed to cool to room temperature and the sample removed. The sample was then washed by immersion in deionised water for about 5 minutes. This was observed to remove most of the salt remaining on the surface of the porous silicon. Samples for 5 elemental analysis were then cleaved from the sample.

The porous silicon sample, which had been treated with manganese nitrate, was washed in water to remove any excess of the unreacted salt on the surface although a clearly marked area was left which indicated where the salt had melted on to the 10 porous silicon substrate. Elemental analysis on a cleaved section (the cleaving occurring at or close to the boundary between the porous and bulk silicon) through the sample was then used to reveal the extent of the manganese impregnation. In all cases, for the manganese, the metal or more probably the metal oxide had reached the bottom of the porous layer, a distance of 30 μ m with the substrates used in these 15 experiments. Manganese was observed only under the area where the molten salt had been. The composition even at the bottom of the pores was sufficient for it to be easily detected by EDX suggesting that it was in excess of one atomic percent. It should be noted that the technique of EDX only allows concentrations of metal in excess of one atomic percent to be detected. For treatment with manganese nitrate, 20 the above procedure was carried out in both a hydrogen atmosphere and in an argon atmosphere. In both types of atmosphere similar concentrations of manganese atoms were observed at similar depths.

The procedure for chromium (II) nitrate, which is consistent with the above 25 mentioned general procedure, was identical to that described for manganese (II) nitrate given above except that the graphite block was heated to 90 C to cause melting and after one hour this temperature was raised to 150 C and maintained at this value for a further hour. The procedure for silver (I) nitrate, which is consistent with the above mentioned general procedure, was identical to that described for 30 manganese (II) nitrate given above except that the graphite block was heated to 250

C to cause melting and after one hour this temperature was raised to 450 C and maintained at this value for a further hour.

EDX analysis for samples of the chromium and silver nitrate treated samples was carried out in a similar way. The treated porous silicon sample was washed in water to remove any excess of the unreacted salt on the surface. Elemental analysis on a cleaved section (the cleaving occurring at or close to the boundary between the porous and bulk silicon) through the sample was then used to reveal the extent of the impregnation of the salt. Chromium oxide (for the chromium nitrate treated sample) had reached the bottom of the porous layer, a distance of 30 μ m with the substrates used in these experiments. Silver (for the silver nitrate treated sample) had reached the bottom of the porous layer, a distance of 30 μ m with the substrates used in these experiments. Unlike the cases of the manganese and chromium treated samples, silver was distributed throughout the pore structure and not just in the area under the melt. The composition even at the bottom of the pores was sufficient for it to be easily detected by EDX suggesting that it was in excess of one atomic percent.

The impregnation procedure for manganese was also carried out in ambient air. Manganese nitrate was placed on the surface of a porous silicon film; the film being placed on a standard laboratory hotplate. The sample was heated on a hotplate to 56C for 70 minutes and 150C for 70 minutes. This gave a black film on the surface of the porous silicon layer. EDX analysis of this film revealed manganese at greater than 1% throughout the layer. There was also a band of higher concentration (a few atomic percent) at a depth of a few microns.

Similar methods to that described here could be used to pass impregnate substances other than metal salts into any porous semiconductor (porous silicon materials being a subset of porous semiconductors). The impregnate

substance could be a metal salt (including the metal nitrates described here) and/or a beneficial substance. The impregnate substance could be an element of the periodic table. Samples of porous silicon, having a sample surface and impregnated by identical or similar methods to those described here, could be used as a component in implants described at other parts of this application.

Invivo trial of Porous Silicon Implant

- 10 The purpose of the trial was to evaluate the biocompatibility of porous silicon when implanted at subcutaneous sites in guinea pigs in order to investigate the materials' suitability for use in implantable devices. The trials were carried out over 1, 4, 12, and 26 weeks.
- 15 Experiments were conducted in accordance with the methods specified in the International Standard for biological evaluation of medical devices part 6 (ISO 10993-6).

The test specimens were in the form of discs (10mm in diameter, 0.3 mm in thickness). Manipulation of their surface characteristics aimed to make 1 specimen type bioactive (ie encourage tissue attachment; hereafter termed porous silicon), 1 specimen type bioinert (ie produce no interaction with living tissues; hereafter termed bulk silicon) and 1 specimen type bioactive pre-coated with hydroxyapatite (hereinafter termed coated porous silicon).
25 One of each specimen type and one control (titanium disc of the same dimensions as the test specimens) were used per animal in the 1, 4, and 12 week study. Two porous silicon samples and two titanium samples were used per animal for the 26 week study.

The 1, 4, and 12 week trials used a total of 30 guinea pigs (10 guinea pigs for each time period). The 26 week trial used a further 5 guinea pigs, making a total of 35 guinea pigs. There was a pilot phase of the trial for seven days prior to the 1, 4, 12, and 26 week periods. The pilot study was 5 carried out on three guinea pigs (one from each of the 1, 4, and 12 week groups). The pilot study was successful (ie no gross reactions to the implants occurred) so the full scale study proceeded as planned.

10 Animals were acclimatised to the Experimental Animal House (EAH) environment for at least 5 days prior to experimentation. Following this period each animal was implanted with a transponder (Biomedic Data Systems) for identification and to enable body temperature to be monitored throughout the procedure. The transponder was implanted subcutaneously via a 12 gauge needle in the dorsal region, at a site where it did not interfere 15 with the subsequent implantation of silicon or control specimens. The area of injection was shaved and a local anaesthetic used.

20 4-7 days later animals were given a general anaesthetic (Halothane 1.5-2.5%) and 4 test specimens implanted. The back of the animal was shaved and an incision of the skin made. Subcutaneous pockets were made by blunt dissection, with the base of the pocket at least 15 mm from the line of the incision. One implant was placed in each pocket, and the implants were at least 5 mm from each other. Four pockets were made to allow placement 25 of 4 implants. The incision was closed by use of appropriate suture material.

30 Body temperature (via the transponder) was measured twice a day following surgery for the duration of the study (including the seven day pilot study). Each of the implant sites was closely examined and the extent of any reaction noted. The diameter of each implant site was measured to assess

swelling and any reddening scored (0 = normal, no different from surround skin; 1 = some light red coloration in patches; 2 = uniform light red coloration or patches of darker red; 3 darker red over all of implant site). At the end of the relevant study period (1, 4, 12 or 26 weeks) animals were
5 killed by an overdose of pentobarbitone. The implant sites were carefully inspected and standard tissue sections of each site were submitted, stained with haematoxylin and eosin and evaluated for various pathological features using a Zeiss Axioplan Photomicroscope. A range of pathological features reflecting the tissue response including acute inflammation and fibrosis
10 were graded by assigning a numerical score to each feature; by comparing score grades with respect to time and implant site, an objective comparison of the silicon materials was obtained. The criteria used in assigning score grades for each pathological feature assessed are summarised in Tables A to D. The specimen type at each implant site was randomised and the
15 experiments and evaluation conducted blind.

The scores or values for each specimen type and each time point were compared with those of the control specimens using appropriate non-parametric tests. Multi-factorial analysis of variance was used where
20 possible, with ad hoc tests for differences between groups.

Mean temperature and weight data is shown in graphical form are shown in figures 7 and 8 respectively. There was a significant rise in temperature (figure 9) and a significant decrease in weight gain (figure 10) for the 7 day
25 period following surgery in all 3 groups of animals (1,4 and 12 weeks). No analogous changes were observed in the 26 week group of animals. Thereafter a steady decline in body temperature and a steady increase in weight was apparent, indicating that no chronic inflammatory reaction to the implants has occurred. The transient effects on temperature and weight

gain are due to the surgical procedure and unrelated to the nature of the implants.

At the time of performing the histological appraisal, the allocation of test and control sites for each experimental animal was unknown and the histological examination was performed blind. Following appraisal, the results were decoded: a summary of the score grades for each implant type with respect to animal number, histological feature and timepoint are summarised in the tables E to H. In general the autopsy examination revealed no evidence of any significant pathological change at any of the three time-points. In particular, all implants were easily extracted from their respective implantation sites and showed no evidence of fibrotic tethering to the surrounding connective tissues. At the earliest time-point each site showed obvious acute inflammation associated with mild to moderate neo-vascularization. At 26 weeks, three out of the twenty sites examined showed mild to moderate chronic inflammation/fibrosis around the vicinity of the implantation site consisting of a cuff of macrophages, lymphocytes and occasional foreign body giant cells. In each case these changes were almost exclusively limited to the implantation site. The histological findings were entirely consistent with the features noted at autopsy. The scores for each of the four classes of pathology (Tables E to H) were compared with respect to time (ie week 1 vs. week 4 vs. week 12 vs week 26) and implant type (the scores of each silicon type compared with the titanium control). Details of the statistical analysis are shown at Tables I and J.

Acute inflammation at week 1 was significantly greater than at weeks 4 and 12 but no difference was found between weeks 4, 12, and 26 (Table I). Tissue degeneration was significantly higher at weeks 1 and 4 when compared to week 12, with no difference between weeks 1 and 4. There was

no significant difference in tissue degeneration/necrosis between test and control samples in any of the weeks. New vessel/granulation tissue formation was significantly higher at weeks 1 and 4 than at weeks 12 and 26; there was no significant difference between weeks 1 and 4. Chronic inflammation was significantly higher at week 4 than at weeks 1, 12 and 26; and it was significantly higher at week 12 than week 1. In general, these significant findings were consistent with the three distinct patterns of pathological change observed at the three excision time-points, summarised below.

10

All sites at one week post-implantation showed features that reflected the immediate response to the injury induced by the surgical procedures to implant the materials. Most sites showed moderate acute inflammation with infiltration of the tissues at the implantation site by neutrophils and macrophages. These changes were associated at the majority sites with oedema of the connective tissues, focal haemorrhage and necrosis and early invasion of the margins of the implant site by proliferating capillary loops. At no site did these changes extend beyond the margins of the implant and into the surrounding skin above or skeletal muscle below.

20

Although a very few sites showed persistent, low grade acute inflammation four weeks post-implantation, the majority of sites showed features that were consistent with the progression of the features described at one week and represented attempts at tissue repair following surgery rather than a reaction to the silicon implant. Most sites showed areas haemorrhage surrounded by loose granulation tissue, active proliferation of new blood vessels and a limited population of active fibroblasts. In a few cases these reparative features extended beyond the implantation site but, even in these cases, did not cause major disruption to the surrounding tissue architecture.

30

By twelve weeks, the histological features represented a maturation of the granulation (repair) tissue response observed at four weeks. Although many of the implantation sites still showed significant infiltration by macrophages, lymphocytes and occasional fibroblasts, they showed no 5 evidence of significant fibrotic scarring and a definite reduction in vascular proliferation. Furthermore, in no case did the persistent pathological change extend beyond the implantation site.

In general after 26 weeks, the implantation sites all showed little evidence 10 of any significant tissue reaction to either the test or standard implants. The sites displaying mild to moderate chronic inflammation around the immediate vicinity of the implantation site consisted of a cuff of macrophages, lymphocytes and occasional foreign body giant cells which did not involve the continuous soft and connective tissues and were not 15 associated with distorting fibrosis of nearby structures.

The major internal organs were also examined at autopsy after 26 weeks implantation, with representative blocks being submitted for routine histopathological examination. In keeping with the observations made at the time of autopsy, 20 histological examination of the major internal organs revealed no evidence of any pathology that could be ascribed to the silicon or titanium implants or any pre-existing disease in the experimental population.

The post-evaluation analysis of the scores for each implant type revealed a 25 significantly higher level of chronic inflammation/fibrosis at weeks 4 and 12 for the porous silicon (uncoated) specimens when compared to the titanium controls (Table J). The nature of the tissue reaction noted is likely to be a reflection of the bioactive nature of the porous silicon implant type, suggesting that this material encourages tissue growth and interacts with 30 biological systems. No other statistically significant differences were

revealed for the other histological features or implant types at any of the time points.

The results of this study clearly demonstrate that there has been little or no reaction either the test or standard implant materials. The significant differences in histological features reflect changes which would be expected from any surgical procedure and are unrelated to the nature of the implant materials.

10 The significant differences in the chronic inflammation scores for the porous silicon at weeks 4 and 12 highlighted by the multivariate analysis are unlikely to be biologically significant in terms of biocompatibility. This conclusion is confirmed by the results of the 26 week study.

15 **Score grades**

Tables A to D indicate the score grade criteria that were used to assess acute inflammatory reaction; tissue degeneration, oedema formation, haemorrhage and skin necrosis; new vessel and granulation tissue formation; and persistent (chronic) inflammation and tissue fibrosis during pathology.

Tables E to H show the pathology score grades for 1, 4, 12, and 26 weeks after implantation, respectively.

25 Table I shows a statistical analysis of the biocompatibility study. For table I average rank of scores for each histology category for each time period. In table I a line between two rows in the significance column indicates a significant difference for those two groups ($p<0.05$: Kruskall-Wallis analysis).

Table J shows statistical analysis of the biocompatibility study. For table J average rank of scores for each implant type by histology category for each time period. In table J “*” denotes a significant difference between the rank for that silicon type in comparison to the titanium control ($p<0.05$; 5 Friedman analysis), where BSi = Bulk silicon, PSi = Porous silicon, CoPSi = Coated porous silicon.

Figures 10 to 13 show the physiological parameters from the biocompatibility study. Figure 10 shows the mean (+/- sem) daily 10 temperature for each of the four groups of guinea pigs. Figure 11 shows mean (+/- sem) daily weight for each of the four groups of guinea pigs. Figure 12 shows a comparison of guinea pig mean (+ sem) temperature for the 7 day control period prior to surgery (week -1, n=30) with the 4 time periods prior to culling each group of animals (week 1, n=35; week 4, 15 n=24¹; week 12, n=14¹; week 26, n=5). The double asterisk “**” shown in Figure 12 indicates $p<0.01$ in comparison to control period. The temperature transponder of 1 animal malfunctioned; data for this animal is therefore missing. Figure 13 shows a comparison of guinea pig mean (+ sem) weight 20 gain for the 7 day control period prior to surgery (week -1, n=30) with the 4 time periods prior to culling each group of animals (week 1, n=35; week 4, n=25; week 12, n=15; week 26, n=5). The double asterisk “***” shown in figure 13 indicates $p<0.01$ in comparison to control period.

Table A

Grade	Description of Histological Features
0.	No histological evidence of any acute inflammatory reaction.
1.	Small discrete clusters of inflammatory cells consisting predominantly of neutrophils and activated macrophages with occasional eosinophils and lymphocytes.
2.	Continuous sheets of acute inflammatory cells showing invasion of connective tissues in the immediate vicinity of the implanted material.
3.	Similar features to 2. above but associated with either necrosis of connective tissues and/or extension of cellular infiltrate beyond the vicinity of the implant.

Table B

Grade	Description of Histological Features.
0.	No histological evidence of oedema, haemorrhage or tissue necrosis.
1.	Mild oedema of the connective tissues in the immediate vicinity of the implant.
2.	Significant oedema associated with either haemorrhage and/or necrosis in the vicinity of the implant.
3.	Similar features to 2. above but extending beyond the implant and involving adjacent connective tissues and muscle.

Table C

Grade	Description of Histological Features
0.	No histological evidence of new vessel formation.
1.	Focal formation of isolated capillary loops in regions of tissue haemorrhage and/or necrosis.
2.	Continuous sheets of new vessel formation in association with local accumulations of fibroblasts to form loose granulation tissue limited to the vicinity of the implant.
3.	Similar features to 2. above but extending beyond the implant and involving adjacent connective tissues and muscle.

Table D

Grade	Description of Histological Features
0.	No histological evidence of either persistent (chronic) inflammation or early deposition of collagen (fibrosis).
1.	Small discrete foci of macrophages and lymphocytes which may or may not be associated with small populations of fibroblasts and new collagen deposition.
2.	Obvious sheets of chronic inflammatory cells and/or discrete granulomata associated with fibrous scar tissue in the vicinity of the implant.
3.	Similar features to 2. above but extending beyond the implant and involving adjacent connective tissues and muscle.

Table E

Group.	Animal No.	Inflammation				Score Grade.				New Vessel/Granulation Tissue.				Chronic Inflammation/Fibrosis.			
		Ti	BSI	PSI	COPSI	Ti	BSI	PSI	COPSI	Ti	BSI	PSI	COPSI	Ti	BSI	PSI	COPSI
+7 Days.	SIGG001.	1	1	1	2	0	0	0	0	1	1	1	2	0	0	0	0
+7 Days.	SIGG002.	2	1	1	1	1	0	0	0	2	1	1	1	0	0	0	0
+7 Days.	SIGG003.	1	1	1	0	0	1	0	0	1	2	1	1	0	0	0	0
+7 Days.	SIGG004.	1	1	2	1	0	0	0	1	1	1	2	1	0	0	0	0
+7 Days.	SIGG005.	1	2	2	2	0	1	1	1	1	2	2	1	0	0	0	0
+7 Days.	SIGG006.	1	1	2	1	0	0	0	1	1	1	1	1	0	0	0	0
+7 Days.	SIGG007.	1	1	1	1	0	0	0	0	1	1	1	1	0	0	0	0
+7 Days.	SIGG008.	1	1	1	1	0	0	0	0	1	1	1	1	0	0	0	0
+7 Days.	SIGG009.	1	1	1	1	0	0	0	0	1	1	1	1	0	0	0	0
+7 Days.	SIGG010.	1	1	1	1	0	0	0	0	1	1	1	1	0	0	0	0

Ti Titanium control
 BSI Bulk Silicon
 PSI Porous Silicon
 COPSI Porous Silicon Coated with hydroxyapatite

Table F

Group.	Animal No.	Inflammation.				Tissue Degeneration/Neutro.				New Vessel/Granulation Tissue.				Chronic Inflammation/Fibrosis.			
		T	BSI	PSI	COPS	T	BSI	PSI	COPS	T	BSI	PSI	COPS	T	BSI	PSI	COPS
+4 Weeks.	SIGG011.	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	2
+4 Weeks.	SIGG012.	0	0	0	0	0	0	0	1	1	1	0	1	2	2	2	1
+4 Weeks.	SIGG013.	0	0	1	0	0	0	0	1	0	1	1	1	1	2	3	2
+4 Weeks.	SIGG014.	0	0	0	0	0	0	0	1	1	0	1	1	2	2	3	3
+4 Weeks.	SIGG015.	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1
+4 Weeks.	SIGG016.	0	0	1	0	0	0	0	1	0	1	1	2	1	2	3	2
+4 Weeks.	SIGG017.	0	0	0	0	0	0	0	1	0	1	1	1	2	2	2	1
+4 Weeks.	SIGG018.	0	0	0	0	0	0	1	0	0	1	0	1	2	1	2	1
+4 Weeks.	SIGG019.	0	0	0	0	0	0	0	1	0	1	1	1	1	2	1	1
+4 Weeks.	SIGG020.	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0

T Titanium control
 BSI Bulk Silicon
 PSI Porous Silicon
 COPS Porous Silicon Coated with hydroxyapatite

Table G

Group.	Animal No.	Inflammation.				Tissue Degeneration/Necrosis.				Score Grade.				Chronic Inflammation/Fibrosis.			
		Ti	Bsi	Psi	Copsi	Ti	Bsi	Psi	Copsi	Ti	Bsi	Psi	Copsi	Ti	Bsi	Psi	Copsi
12 Weeks	SIGG021.	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
12 Weeks	SIGG022.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12 Weeks	SIGG023.	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2
12 Weeks	SIGG024.	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
12 Weeks	SIGG025.	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
12 Weeks	SIGG026.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
12 Weeks	SIGG027.	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
12 Weeks	SIGG028.	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0
12 Weeks	SIGG029.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2
12 Weeks	SIGG030.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0

Ti Titanium control
 Bsi Bulk Silicon
 Psi Porous Silicon
 Copsi Porous Silicon Coated with hydroxyapatite

Table H

Group.	Animal No.	Inflammation			Tissue Degeneration/Histology			New Vessel/Granulation Tissue.			Scar Grade.			Chronic Inflammation/Fibrosis.		
		T1	T1	PSI	T1	PSI	PSI	T1	PSI	Psi	T1	PSI	Psi	T1	PSI	Psi
+26 weeks.	SIGG031.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
+26 weeks.	SIGG032.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
+26 weeks.	SIGG033.	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
+26 weeks.	SIGG034.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
+26 weeks.	SIGG035.	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
+26 weeks.	SIGG036.	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

T1 Titanium control

PSI Porous Silicon

N/A : Not applicable, control (non-implanted animal).

Table I

Group	Inflammation			Tissue Degeneration/Necrosis			New vessels/Granulation Tissue			Chronic Inflammation/Fibrosis		
	Average	Significance rank	Average	Significance rank	Average	Significance rank	Average	Significance rank	Average	Significance rank	Average	Significance rank
Week 1	112.5	>	73.6				99.2			40.0	>>>	
Week 4	50.2	>	71.9				76.8	>	>	104.4	>	
Week 12	47.0		60.4				41.2			65.1		
Week 26	47.0		58.5				29.0			51.5		

Table J

Group	Implant Type	Inflammation	Tissue Degeneration	New Vessels/ Granulation	Average Rank	
						Chronic Inflammation/ Fibrosis
Week 1	Titanium	2.4	2.45	2.5	2.5	2.5
	BSi	2.4	2.45	2.5	2.5	2.5
	PSi	2.8	2.65	2.5	2.5	2.5
	CoPSi	2.4	2.45	2.5	2.5	2.5
Week 4	Titanium	2.4	2.1	2.15	1.85	1.85
	BSi	2.4	2.3	2.75	2.70	2.70
	PSi	2.8	2.5	2.75	3.20*	3.20*
	CoPSi	2.4	3.1	2.35	2.25	2.25
Week 12	Titanium	2.5	2.44	2.33	2.11	2.11
	BSi	2.5	2.44	2.33	2.11	2.11
	PSi	2.5	2.67	3.00	3.33*	3.33*
	CoPSi	2.5	2.44	2.33	2.44	2.44
Week 28	Titanium	1.5	1.5	1.5	1.33	1.33
	PSi	1.5	1.5	1.5	1.67	1.67

CLAIMS.

1. A silicon implant having a beneficial substance associated with it, the implant being eroded when implanted in a mammalian body.
2. A silicon implant according to claim 1 in which the implant comprises porous silicon.
3. A silicon implant according to claim 1 which comprises polycrystalline silicon.
4. A silicon implant according to any preceding claim which is resorbed when implanted in a mammalian body.
5. A silicon implant according to any preceding claim which if left in the mammalian body for long enough is substantially completely resorbed.
6. A silicon implant according to any preceding claim in which said beneficial substance comprises an element of the periodic table.
7. A silicon implant according to claim 6 in which the element is a micromineral.
8. A silicon implant according to claim 7 in which the micromineral is from the group: selenium, manganese, molybdenum, chromium, vanadium, iodine, fluorine, cobalt (vitamin B12).
9. A silicon implant according to claim 6 in which the element is an essential trace element identified as such in Figure 5.

10. A silicon implant according to claim 6 in which the element is a therapeutic element.
11. A silicon implant according to claim 10 in which the element is from the group: lithium, gold, silver, platinum.
12. A silicon implant according to any preceding claim in which the substance is distributed through a volume of the material of said implant.
13. A silicon implant according to claim 11 in which the substance is distributed through substantially the whole volume of the material of the implant.
14. A silicon implant according to any preceding claim which comprises at least a region of porous silicon.
15. A silicon implant according to claim 14 which comprises substantially entirely porous silicon.
16. A silicon implant according to claim 14 or claim 15 which has a porosity of at least 3%, 4% or 5%.
17. A silicon implant according to any one of claims 14 to 15 which has a porosity of 30% or less.
18. A silicon implant according to any one of claims 14 to 16 which has a porosity in the range 3% to 10%, or in the range 10% to 60%.
19. A silicon implant according to any preceding claim in which there is provided a reservoir of beneficial substance, and a door leading to the

50

reservoir, the door being made of silicon material which is corroded in use so as to enable body fluid to contact the beneficial substance in the reservoir.

20. A silicon implant according to claim 19 in which there are a plurality of reservoirs.

21. A silicon implant according to claim 19 or claim 20 in which the reservoirs are adapted to expose or release their contents to body fluids sequentially with time.

22. A silicon implant according to any one of claims 19 to 21 in which there are a plurality of reservoirs, each having an associated door, and in which there are doors of different corrosion times, such that in use the reservoirs are breached at different times.

23. A silicon implant according to claim 22 in which there are doors of different thicknesses.

24. A silicon implant according to claim 22 in which there are doors which corrode at different rates.

25. A silicon implant according to any one of claims 19 to 24 in which there is an array of reservoirs.

26. A silicon implant according to any one of claims 19 to 25 in which the reservoirs comprise holes which contain the beneficial substance.

27. A silicon implant according to any one of claims 19 to 25 in which the reservoirs comprise regions of the implants which differentially contain

the beneficial substance to a significantly higher level than adjacent, non-reservoir, regions of the implant.

28. A silicon implant according to any one of claims 19 to 27 which comprises a first component defining in part a boundary of the or each reservoir and a second component defining in part a boundary of the or each reservoir.

29. A silicon implant according to claim 28 in which the two components are substantially the same.

30. A silicon implant according to any one of claims 19 to 29 in which there are at least of the order of ten, and preferably at least of the order of a hundred, reservoirs.

31. A silicon implant according to claim 30 in which there are at least or the order of a thousand reservoirs.

32. A silicon implant according to any one of claims 19 to 31 that has been micromachined.

33. An implant comprising a porous or polycrystalline carrier material that is corrode by mammalian subcutaneous physiological fluids, and a beneficial substance associated with the carrier material.

34. An implant according to claim 33 in which the carrier material is a semiconductor.

35. An implant according to claim 34 in which the carrier material is from the doped or undoped group: silicon, germanium, silicon carbide, silicon nitride.

36. An implant according to any one of claims 33 to 35 in which the implant comprises porous or polycrystalline semiconductor material.

37. An implant according to any one of claims 33 to 36 in which the beneficial substance comprises an element of the period table.

38. An implant according to claim 36 in which the element is a micromineral.

39. An implant according to claim 36 and any one of claims 1 to 35 in which instead of silicon another semiconductor material comprises the material that is eroded in use.

40. A silicon implant substantially as described herein with reference to Figures 4A to 4C and Figure 5 of the accompanying drawings.

41. A silicon implant substantially as described herein with reference to Figure 6, or Figure 7, or Figure 8, or Figure 9 of the accompanying drawings.

42. A method of making a silicon implant for the delivery of a beneficial substance to a subject, the method comprising taking a body of silicon, forming the silicon into an implantable implant, and introducing a beneficial substance into the silicon.

43. A method according to claim 42 which comprises applying a solution of micromineral to the silicon and migrating the micromineral into the silicon.
44. A method according to claim 42 or claim 43 comprising driving the beneficial substance into the silicon using heat.
45. A method according to any one of claims 42 to 44 comprising micromachining a hole or recess in the silicon.
46. A method according to claim 45 further comprising introducing said beneficial substance into the hole.
47. A method according to any one of claims 43 to 46 comprising applying a lid, or door, over the region which contains the beneficial substance to retain the beneficial substance.
48. A method according to any one of claims 45 to 47 comprising making a hole in a first component of silicon, making a complementary hole in a second piece of silicon, introducing said beneficial substance into one or both holes, and joining the two components together with their holes in register to define a closed reservoir which contains said beneficial substance.
49. A method according to any one of claims 45 to 48 comprising making a large number of holes in the implant, preferably simultaneously.
50. A method according to claim 49 which uses a photolithographic technique to make the holes.

51. A method according to any one of claims 42 to 50 comprising treating the body of silicon to make at least part of it porous.

52. A method according to claim 51 comprising making a body of silicon porous throughout substantially the whole of its volume.

53. A method according to any one of claims 42 to 50 comprising taking, or creating, a polycrystalline silicon body of material, or a layer or region of polycrystalline silicon.

54.. A method of making a semiconductor implant for the delivery of a beneficial substance to a subject, the method comprising taking a body of semiconductor, forming the semiconductor into an implantable implant, and introducing a beneficial substance into the semiconductor.

55. A method according to claim 54 in which the semiconductor is from the group: silicon, germanium.

56. A method according to claim 54 or claim 55 comprising introducing a micromineral to the semiconductor.

57. A method according to any one of claims 54 to 56 and in accordance with any one of claims 42 to 53, in which the silicon material need not be silicon but could be another semiconductor.

58. A method of making a semiconductor implant substantially as described herein.

59. A method of making an implant for the delivery of beneficial substance to a subject, the method comprising treating a porous member of

material that is erodable in vivo, creating an implant from the member, and introducing a beneficial substance into the implant.

60. An implant having a plurality of reservoirs, a plurality of beneficial substance charges provided in said reservoirs, and a plurality of barrier regions, or doors, provided adjacent said reservoirs, the doors having a plurality of different erosion times when implanted, the arrangement being such that in use the doors are broken down sequentially in order to stagger the release of the contents of the reservoirs.

61. An implant according to claim 60 in which the doors comprise a semiconductor material.

62. An implant according to claim 60 or claim 61 in which substantially the entire implant comprises semiconductor material.

63. An implant according to claim 62 in which the implant comprises the same semiconductor material throughout.

64. An implant according to any one of claims 60 to 63 in which there are at least five reservoirs.

65. An implant according to claim 64 in which there are at least ten reservoirs.

66. An implant according to claim 64 in which there are at least fifty reservoirs.

67. An implant according to claim 64 in which there are at least one hundred reservoirs.

68. An implant according to claim 64 in which there are at least of the order of hundreds of reservoirs.

69. A method of delivering a beneficial substance to a subject comprising implanting an implant into the subject and arranging for different regions of the implant to be eroded through or away at different times by arranging for said regions to require different exposure times to the corroding fluids experienced in use to be breached, and using the sequential breaching of said different regions to release sequentially different reservoirs of beneficial substance that were retained in or behind said different regions of the implant.

70. The use of corrodable or resorbable silicon, or other semiconductor material, in the preparation of an implant for the delivery of a physiologically active substance to a subject.

71. The use of the corrosion or resorption of silicon or other semiconductor material in an implant in order to release a substance entrained in the material of the silicon or semiconductor, or to open a door to a reservoir of the substance.

72 A silicon implant according to any one of Claims 6, 7, 9, 10, and 11 characterised in that the implant comprises a porous silicon sample having a sample surface, the element being present at a concentration between 1 and 90 atomic percent at a depth, from the sample surface, between 0.35 μ m and 1000 μ m.

73 A silicon implant according to Claim 72 characterised in that the element is present at a concentration between 1 and 50 atomic percent at a depth, from the sample surface, between 0.35 µm and 100µm.

74 A silicon implant according to Claim 72 characterised in that the element is present at a concentration between 1 and 10 atomic percent at a depth, from the sample surface, between 0.35 µm and 100µm.

75 A silicon implant according to Claim 72 characterised in that the element is present at a concentration between 1 and 10 atomic percent at a depth, from the sample surface, between 20µm and 30µm.

76 A method according to Claim 54 characterised in that the method comprises the further step of treating the body of semiconductor to make at least part of it porous.

77 A method according to Claim 76 characterised in that the step of introducing the beneficial substance comprises the steps:

- (a) bringing the beneficial substance into contact with the porous part of the semiconductor;
- (b) causing the beneficial substance to be in a molten phase; and
- (c) allowing the molten beneficial substance to pass into the porous part of the semiconductor.

78 A method according to Claim 77 characterised in that the passage of the beneficial substance into the porous semiconductor is assisted by the application of heat to the porous semiconductor.

79 A method according to Claim 77 characterised in that the method further comprises the step of thermally decomposing the beneficial substance that has passed into the porous semiconducting material.

80 A method according to Claim 77 characterised in that the method comprises the step of reacting the beneficial substance that has passed into the semiconductor material with an oxidant.

81 A method according to any one of Claims 76 to 80 characterised in that the semiconductor is silicon.

82 A method of impregnating a porous semiconducting material with an impregnate substance, the method comprising the step of bringing the impregnate substance into contact with the porous semiconducting material; characterised in that the method further comprises the steps:

- (a) causing the impregnate substance to be in a molten phase; and
- (b) allowing the molten impregnate substance to pass into the porous semiconducting material.

83 A method according to Claim 82 characterised in that the passage of the impregnate substance into the porous semiconductor is assisted by the application of heat to the porous semiconductor.

84 A method according to Claim 82 characterised in that the method further comprises the step of thermally decomposing the impregnate substance that has passed into the porous semiconducting material.

85 A method according to Claim 82 characterised in that the method comprises the step of reacting the impregnate substance that has passed into the semiconductor material with an oxidant.

86 A method according to any one of Claims 82 to 85 characterised in that the impregnate substance comprises a metal salt.

87 A method according to Claim 86 characterised in that the impregnate substance comprises two or more metal salts.

88 A method according to Claim 86 characterised in that the metal salt is manganese nitrate or chromium nitrate or silver nitrate or calcium nitrate.

89 A method according to Claim 86 characterised in that the metal salt is a salt of one or more the transition metals or the rare earth metals.

90 A method according to Claim 86 characterised in that the salt is a nitrate or an alkoxide or a beta-diketone, or a mixed alkoxide/beta-diketone.

91 A method according to Claim 86 characterised in that the salt has a melting point less than 800 C.

92 A method according to Claim 86 characterised in that the salt has a melting point less than 400 C.

93 A method according to Claim 86 characterised in that the salt has a melting point between 0 C and 150 C.

94 A method according to any one of Claims 82 to 93 characterised in that the porous semiconducting material is porous silicon.

95 A method according to Claim 94 characterised in that the porous silicon has a porosity in the range 3% to to 60%.

96 A sample of porous silicon that has been impregnated with an impregnate substance, the sample having a sample surface and the impregnate substance comprising an impregnate element. characterised in that the impregnate element is present at a concentration between 1 and 90 atomic percent at a depth, from the sample surface, between 0.35 μ m and 1000 μ m.

97 A sample according to Claim 96 characterised in that the impregnate element is present at a concentration between 1 and 50 atomic percent at a depth, from the sample surface, between 0.35 μ m and 100 μ m.

98 A sample according to Claim 96 characterised in that the impregnate element is present at a concentration between 1 and 10 atomic percent at a depth, from the sample surface, between 0.35 μ m and 100 μ m.

99 A sample according to Claim 96 characterised in that the impregnate element is present at a concentration between 1 and 10 atomic percent at a depth, from the sample surface, between 20 μ m and 30 μ m.

100 A sample according to any one of Claims 96 to 99 characterised in that the impregnate element comprises a metal.

101 A sample according to Claim 100 characterised in that the metal is manganese, chromium, silver or calcium.

102 A sample according to Claim 100 characterised in that the metal is a transition metal or a rare earth metal

103 A method according to any one of Claims 77 to 81 characterised in that the beneficial substance substantially consists of a metal salt.

104 A method according to any one of Claims 77 to 81 characterised in that the beneficial substance substantially consists of a mixture of two or more metal salts.

105 A method according to any one of Claims 77 to 81 characterised in that the beneficial substance is a solid at 293 K and 760 mmHg.

106 A method according to any one of Claims 82 to 86 or any one of Claims 88 to 93 characterised in that the impregnate substance substantially consists of a metal salt.

107 A method according to any one of Claims 87 characterised in that the impregnate substance substantially consists of a mixture of two or more metal salts.

108 A method according to any one of Claims 82 to 85 characterised in that the impregnate substance is a solid at 293 K and 760 mmHg.

109 A silicon implant according to Claim 73 characterised in that the element is present at a concentration between 1 and 50 atomic percent at a depth, from the sample surface, between 10 µm and 100µm.

110 A silicon implant according to Claim 74 characterised in that the element is present at a concentration between 1 and 10 atomic percent at a depth, from the sample surface, between 10 µm and 100µm.

111 A sample according to Claim 97 characterised in that the impregnate element is present at a concentration between 1 and 50 atomic percent at a depth, from the sample surface, between 10 µm and 100µm.

112 A sample according to Claim 98 characterised in that the impregnate element is present at a concentration between 1 and 10 atomic percent at a depth, from the sample surface, between 10 µm and 100µm.





Fig. 1A.**Fig. 1B.****Fig. 1C.****Fig. 1D.**

Fig.2B.




Fig.2C.





Fig.3A.




Fig.3C.




Fig.3B.





Fig.3D.



4/9




Fig.4A.**Fig.4B.****Fig.4C.**

Fig.5.

	Trace Elements		Essential		Practical Problems: Deficiency		Practical Problems: Excess		M Practical Problems In Man ? Essentiality Questioned By Some. (3 U,82 Pb)		2 He	
1 H	4 Be		3 Li	12 Mg	5 B	6 C	7 N	8 O	9 F	10 Ne		
11 Na		13 Al	14 Si		15 P	16 S	17 Cl		18 Ar			
19 K	20 Ca	21 Sc	22 Ti	23 V	24 Cr	25 Mn	26 Fe	27 Co	28 Ni	29 Cu	30 Zn	31 Ga
37 Rb	38 Sr	39 Y	40 Zr	41 Nb	42 Mo	43 Tc	44 Ru	45 Rh	46 Pd	47 Ag	48 Cd	49 In
55 Cs	56 Ba	57 La	58 Hf	59 Ta	60 W	61 Re	62 Os	63 Ir	64 Pt	65 Au	66 Hg	67 Tl
										68 Pb	69 Bi	70 Po
										71 At	72 Rn	73 Kr

6/9

Fig.6.




Fig.7.




Fig.8.






Fig.9.



SUBSTITUTE SHEET (RULE 26)


7/9

Fig.10.



8/9

Fig. 11.



9/9

Fig.12.





Fig.13.



INTERNATIONAL SEARCH REPORT

Internatir	Application No
	PCT/GB 99/01185

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/00 A61K47/34 A61K47/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 97 06101 A (SECRETARY OF STATE FOR DEFENCE, UK) 20 February 1997 (1997-02-20)</p> <p>claims 1,2,5-7,9-16,18-23,25-35,38,39 page 14, line 1 -page 16, line 6 figures page 17, line 4 - line 14</p>	1-7,9, 10, 12-20, 25,26, 32-38, 42-56, 58-60, 62,63, 70,71, 76,78, 81,86, 103

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

5 October 1999

Date of mailing of the international search report

11/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarpioni, U

INTERNATIONAL SEARCH REPORT

In relation on patent family members

International Application No

PCT/GB 99/01185

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9706101	A 20-02-1997	GB	2303847 A	05-03-1997
		AU	6626496 A	05-03-1997
		CA	2228426 A	20-02-1997
		EP	0842113 A	20-05-1998
		GB	2317885 A	08-04-1998

PATENT COOPERATION TREATY

PCT

REC'D 02 JUN 2000

WIPO PCT

15

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference IPD/P2638/WOD	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/GB99/01185	International filing date (day/month/year) 16/04/1999	Priority date (day/month/year) 17/04/1998
International Patent Classification (IPC) or national classification and IPC A61K9/00		
Applicant THE SECRETARY OF STATE FOR DEFENCE... et al.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input checked="" type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input checked="" type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application 		

Date of submission of the demand 05/11/1999	Date of completion of this report 3 U. 05. 00
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Paloniemi Legland, R Telephone No. +49 89 2399 7315



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB99/01185

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-47 as originally filed

Claims, No.:

1-112 as originally filed

Drawings, sheets:

1/9-9/9 as originally filed

2. The amendments have resulted in the cancellation of:

- the description, pages:
 the claims, Nos.:
 the drawings, sheets:

3. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- restricted the claims.
 paid additional fees.
 paid additional fees under protest.
 neither restricted nor paid additional fees.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB99/01185

2. This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
 - complied with.
 - not complied with for the following reasons:
see separate sheet
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
 - all parts.
 - the parts relating to claims Nos. 1-32, 42-53, 70-75, 109-110.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims 8,11,21-24,27-31,46-50,72-75,109-110
	No:	Claims 1-7,9-10,12-20,25-26,42-45,51-53,70-71
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-32,42-53,70-75,109-110
Industrial applicability (IA)	Yes:	Claims 1-32,42-53,70-75,109-110
	No:	Claims

2. Citations and explanations

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/01185

Re Item IV

Lack of unity of invention

The Examining Division makes an objection concerning the lack of unity (Art. 13 PCT). The application contains several independent claims where alternative solutions to one technical problem are claimed as well as independent claims where solutions to more than one technical problem are claimed.

The separate inventions are:

A) One technical problem with alternative solutions

1. to provide a tissue-compatible **implant** for delivering low payloads of a therapeutic substance to a specific site and/or over a long period of time

by using a **silicon implant** having beneficial substance associated with it, the implant being eroded when implanted in a mammalian body

(Claims: 1-32, 42-53, 70-75, 109-110)

2. to provide a tissue-compatible **implant** for delivering low payloads of a therapeutic substance to a specific site and/or over a long period of time

by using an **implant** comprising a porous or polycrystalline carrier material that is corrode by mammalian subcutaneous physiological fluids, and a beneficial substance associated with the carrier material

(Claims: 33-39 and 59)

3. to provide a tissue-compatible **implant** for delivering low payloads of a therapeutic substance to a specific site and/or over a long period of time

by using an **implant** having a plurality of reservoirs, a plurality of beneficial substance charges provided in said reservoirs, the doors having a plurality of different erosion times when implanted, the arrangement being such that in use the doors are broken down sequentially in order to stagger the release of the contents of the reservoirs

(Claims: 60-69)

The above inventions 1-3 do not share either the same Special Technical Feature or any corresponding Special Technical Feature.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/01185

B) Solutions to more than one technical problem

4. to provide a method for making a **semiconductor implant** for the delivery of a beneficial substance to a subject

by taking a body of semiconductor, forming the semiconductor into an implantable implant, and introducing a beneficial substance into the semiconductor

(Claims: 54-56, 76-81 and 104-105)

5. to provide a method for **impregnating a porous semiconducting material** with an impregnating substance

by bringing the impregnate substance into contact with the porous semiconducting material comprising the steps: (a) causing the impregnate substance to be in a molten phase and (b) allowing the molten impregnate substance to pass into the porous semiconducting material

(Claims: 82-95, 106 and 108)

6. to provide a **porous sample** with an impregnate substance for every possible purpose

by providing a sample of impregnated porous silicon, that sample having a sample surface and comprising an impregnate element

(Claims: 96-102 and 111-112)

The inventions of group **A**) and 4., 5. and 6. are a group of independent problems, each of which can be solved without reference to the others. An inventive activity is necessary to get from the one problem to another, there are no linear linked series of problems.

The claims concerning the technical problem how to provide a tissue-compatible implant for delivering low payloads of a therapeutic substance to a specific site and/or over a long period of time, wherein the solution is to use a silicon implant having a beneficial substance associated with it said implant being eroded when implanted in a mammalian body, have been examined (claims: 1-32, 42-53, 70-75 and 109-110).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/01185

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following document:

D1: WO 97 06101 A (SECRETARY OF STATE FOR DEFENCE,UK) 20 February 1997 (1997-02-20)

Claim 1 is directed to a **silicon implant** having a beneficial substance associated with it, the implant being eroded when implanted in a mammalian body. Document D1 discloses bioactive silicon used in drug delivery systems and in surgical implants (p.16, I.5-6; p.17, I.7; p.22, I.13-14). The other features in dependent claims are also known from D1: "porous, polycrystalline silicon which is resorbed when implanted in a mammalian body" (p.14, I.15-19; p. 17, I.4-7; claims 12 and 37), "beneficial substance comprises calcium" (p.15, I.1), "porosity 4-70 %" (claim 12), "substance distributed through the material of implant", "plurality of reservoirs with holes" (Figures). Therefore the subject-matter of claims 2-7, 9-10, 12-20, 25-26 and 32 is not novel (Art. 33(2) PCT).

Claim 42 is directed to a **method of making a (silicon) implant** which method is as well known from D1 (claims 27-31). The features in dependent method claims 43-45 and 51-53 are disclosed in D1 (p.21, 23, claims 10 and 37). Claims 70 and 71 are directed to the **use of silicon** in the preparation of an implant which use is also disclosed in D1 (p.16-17). Therefore the subject-matter of claims 42, 70 and 71 is not novel.

The other dependent implant and method claims do not contain any features, which in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of inventive step. These claims merely contain arbitrary selected features without showing any unexpected effects. Thus the subject-matter of claims 8, 11, 21-24, 27-31, 46-50, 72-75 and 109-110 does not involve an inventive step.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB99/01185

Re Item VII

Certain defects in the international application

Contrary to the requirements of Rule 5.1(a)(ii) and (iii) PCT, the relevant background art (D1) is not indicated in the description and no corresponding document has been cited. The claims may not contain drawings (claim 9) (Rule 11.10(a) PCT). The unit "atomic percent" (for a concentration) employed on claims 72-75 and 109-110 is not additionally expressed in terms of the units stipulated by Rule 10.1(a) PCT.